It known as a specific therapy mainly because it exclusively targets the CD38  that are overexpressed to the multiple myeloma cells. Daratumumab is from a class of medicines identified as CD38 monoclonal antibodies.  These are biological products that have by now been approved from the FDA, versus which biosimilar merchandise are compared. The